EVERADS’S PLATFORM DELIVERY SYSTEM
Delivering retinal therapies via the suprachoroidal space
Effective
Targeted delivery of the therapeutic agent to choroid and retina, with excellent distribution
Potential for longer lasting effect
Applicable for small and large molecules, gene and cell therapy
Safe
Posterior segment reach does not interfere with the visual axis and does not involve the
anterior chamber, minimizing potential side effects (IOP, cataract)
News
(July 12, 2020)
Everads Therapy featured on European Union's CORDIS website:
The European Union has selected Everads for a publication in the ‘Results in Brief’ section of the European Commission’s CORDIS website. (read more...)
(March 12, 2020)
Everads Therapy Enters Into Option Agreement With Global Pharma Company to License Everads' Suprachoroidal Delivery System for Retinal Disease Therapies;
- Agreement Supports Potential of Everads' Novel Technology and Method for Delivery of Posterior Segment Therapeutics to the Suprachoroidal Space. (read more...)
CONTACT US
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 882359